Laily UPN

The Architect of the AI Hospital: How Sheba Medical Center Became OpenAI’s First International Healthcare Partner the-architect-of-the-ai-hospital-how-sheba-medical-center-became-openais-first-international-healthcare-partner

The Architect of the AI Hospital: How Sheba Medical Center Became OpenAI’s First International Healthcare Partner

Laily UPN September 2, 2026

In the rapidly evolving landscape of medical technology, a pivotal shift is occurring within the walls of...

Finding Stillness in the Storm: A 10-Minute Yoga Protocol for Modern Stress finding-stillness-in-the-storm-a-10-minute-yoga-protocol-for-modern-stress

Finding Stillness in the Storm: A 10-Minute Yoga Protocol for Modern Stress

Laily UPN September 2, 2026

Published: September 1, 2026 As the calendar turns to September, the collective rhythm of society undergoes a...

The AI Revolution in Genomic Diagnostics: Streamlining the Path to Answers for Rare Diseases the-ai-revolution-in-genomic-diagnostics-streamlining-the-path-to-answers-for-rare-diseases

The AI Revolution in Genomic Diagnostics: Streamlining the Path to Answers for Rare Diseases

Laily UPN September 1, 2026

For thousands of families worldwide, the search for a medical diagnosis for a child with a rare...

Global Solidarity in Action: Riyadh Humanitarian Forum Charts New Course for Crisis Response global-solidarity-in-action-riyadh-humanitarian-forum-charts-new-course-for-crisis-response

Global Solidarity in Action: Riyadh Humanitarian Forum Charts New Course for Crisis Response

Laily UPN August 31, 2026

RIYADH – On February 24–25, 2025, the global humanitarian community converged in the Saudi capital for the...

Breakthrough in Breast Cancer Care: Targeting Dormant Cells Offers New Hope for Preventing Recurrence breakthrough-in-breast-cancer-care-targeting-dormant-cells-offers-new-hope-for-preventing-recurrence

Breakthrough in Breast Cancer Care: Targeting Dormant Cells Offers New Hope for Preventing Recurrence

Laily UPN August 30, 2026

PHILADELPHIA, PA – [Insert Date of Publication, e.g., November 27, 2023] – In a monumental leap forward...

The Architecture of Trust: How KFF Sets the Gold Standard in Modern Survey Research the-architecture-of-trust-how-kff-sets-the-gold-standard-in-modern-survey-research

The Architecture of Trust: How KFF Sets the Gold Standard in Modern Survey Research

Laily UPN August 29, 2026

In an era defined by fractured information ecosystems and declining public trust in institutions, the role of...

Advocacy in Action: METAvivor Calls on Congress to Secure Future of National Cancer Registries advocacy-in-action-metavivor-calls-on-congress-to-secure-future-of-national-cancer-registries

Advocacy in Action: METAvivor Calls on Congress to Secure Future of National Cancer Registries

Laily UPN August 28, 2026

In the complex ecosystem of American public health, few tools are as vital—or as chronically underappreciated—as the...

A New Era in Oncology: Revolution Medicines Launches Rasonque for Metastatic Pancreatic Cancer a-new-era-in-oncology-revolution-medicines-launches-rasonque-for-metastatic-pancreatic-cancer

A New Era in Oncology: Revolution Medicines Launches Rasonque for Metastatic Pancreatic Cancer

Laily UPN August 28, 2026

The landscape of oncology has shifted dramatically this week with the commercial launch of Rasonque (daraxonrasib), a...

AstraZeneca and Amgen’s Tezspire Eyes Blockbuster Status with Eosinophilic Esophagitis Breakthrough astrazeneca-and-amgens-tezspire-eyes-blockbuster-status-with-eosinophilic-esophagitis-breakthrough

AstraZeneca and Amgen’s Tezspire Eyes Blockbuster Status with Eosinophilic Esophagitis Breakthrough

Laily UPN August 28, 2026

By Delilah Alvarado Published August 27, 2026 AstraZeneca and Amgen have announced a significant clinical milestone for...

Tezspire Poised for New Indication in Eosinophilic Esophagitis Following Promising Phase III Trial Results tezspire-poised-for-new-indication-in-eosinophilic-esophagitis-following-promising-phase-iii-trial-results

Tezspire Poised for New Indication in Eosinophilic Esophagitis Following Promising Phase III Trial Results

Laily UPN August 27, 2026

Amgen and AstraZeneca’s Tezspire (tezepelumab) has achieved a significant milestone with positive results from the Phase III...

The Architect of the AI Hospital: How Sheba Medical Center Became OpenAI’s First International Healthcare Partner

Finding Stillness in the Storm: A 10-Minute Yoga Protocol for Modern Stress

The AI Revolution in Genomic Diagnostics: Streamlining the Path to Answers for Rare Diseases

Global Solidarity in Action: Riyadh Humanitarian Forum Charts New Course for Crisis Response

Breakthrough in Breast Cancer Care: Targeting Dormant Cells Offers New Hope for Preventing Recurrence

The Architecture of Trust: How KFF Sets the Gold Standard in Modern Survey Research

Advocacy in Action: METAvivor Calls on Congress to Secure Future of National Cancer Registries

A New Era in Oncology: Revolution Medicines Launches Rasonque for Metastatic Pancreatic Cancer

AstraZeneca and Amgen’s Tezspire Eyes Blockbuster Status with Eosinophilic Esophagitis Breakthrough

Tezspire Poised for New Indication in Eosinophilic Esophagitis Following Promising Phase III Trial Results

You may have missed

A New Titan in Oncology: Telix’s $1.65 Billion Acquisition of ITM Reshapes the Radiopharmaceutical Landscape

A New Era of Health Sovereignty: WHO and African Union Forge Strategic Alliance to Redefine Continental Wellness

A Historic Victory: Timor-Leste Achieves Malaria-Free Certification

A New Era for Genomic Science: ASHG Announces Strategic Publishing Partnership with Oxford University Press